The present study describes combined transcriptome and metabolome analysis for therapeutic target validation in hypoxia-induced vascular remodeling. Exposure to hypoxic conditions resulted in the upregulation of S100C mRNA and increased taurine (2-aminoethanesulfonic acid) content in the rat lung, as demonstrated by differential display and amino-acid content analysis. Hypoxia resulted in transcriptional activation of the S100C promoter through hypoxia-inducible factor-1 (HIF-1). Taurine suppressed HIF-1-mediated increases in S100C transcription. Moreover, oral taurine administration attenuated vascular remodeling in hypoxic rat lung, whereas depletion of endogenous taurine by administration of beta-alanine resulted in increased vascular remodeling. Inhibition of HIF transcription by taurine may be of therapeutic benefit in preventing hypoxia-induced vascular remodeling. In conclusion, we used transcriptome and metabolome analysis to identify a therapeutic low-molecular-weight ligand that plays a critical role in hypoxia-induced vascular remodeling. These techniques provided an excellent strategy for screening and validation of targets.
INTRODUCTION
Gene expression profiling through pharmacogenomic transcriptome analysis can identify novel, therapeutic targets in various disease states. Furthermore, simultaneous identification and quantification of biogenetically synthesized metabolites (metabolome) highlight molecular mechanisms, providing a link between low-molecular-weight metabolites and expression of genes or gene products.
Hypoxia induces alterations in gene expression and pathophysiology. [1] [2] [3] Exposure to chronic hypoxia results in sustained pulmonary hypertension secondary to muscularization and medial hypertrophy of the pulmonary vasculature. However, the mechanism by which this occurs is not clear. Thus, the goal of the current study was to utilize transcriptome and metabolome analysis to identify a therapeutic low-molecular-weight ligand involved in hypoxia-induced vascular remodeling.
RESULTS

Fluorescent differential display (FDD)
analysis was employed to screen for the upregulated or downregulated gene products in the hypoxic rat lung, 4, 5 and 101 fragments from areas, which represented altered transcription were subcloned. In all, 23 fragments of them revealed the sequence homology for genes whose response to hypoxia had been reported such as insulin-like growth factor, one of the known hypoxia-inducible factor (HIF) target gene. In other group of fragments, one candidate had a sequence identical to S100C cDNA 6 ( Figure 1a ). Protein expression of S100C was upregulated between 12 and 48 h of hypoxia (Figure 1b) . We assessed the regulatory elements that delineate hypoxic upregulation of the S100C gene. By sequence analysis, we identified two putative hypoxia-inducible factor-1 (HIF-1) consensus-binding sites at positions À1695 and À1203 of the S100C promoter. 7 We then produced a construct composed of a 1.9 kb fragment of the S100C promoter region (À1948 to +93) attached to the luciferase gene (pS100CLUCÀ1948/+93) ( Figure 2a ). Transient transfection experiments indicated that the S100C promoter fragment was able to drive transcription of the luciferase-reporter construct when tested in HeLa cells under normoxic condition. Hypoxic incubation for 24 h significantly increased the S100C-driven luciferase activity. Deletion of 5 0 -flanking DNA from À1948 to À1591 did not affect the response to hypoxia, whereas deletion of sequence from À1591 to À1134 resulted in a reporter that was unresponsive to hypoxia ( Figure 2b ). Site-directed mutation of each putative HIF-1 consensus site or both sites was performed. Mutation of the -1695 HIF-1 site (MutA) decreased the response to hypoxia, whereas mutation of À1203 HIF-1 site (MutB) or both sites (MutAB) completely abolished the response to hypoxia (Figure 2c ). These findings indicate that the HIF-1 consensus site at À1203 is required for the S100C response to hypoxia, and the HIF-1 consensus site at À1695 mediates only a small portion of the hypoxic response.
Hypoxia-induced alterations in rat lung amino-acid content were investigated by metabolome analysis. Taurine content was most abundant and upregulated at 3 and 7 days of hypoxia (Figure 1c) , whereas the content of other essential amino acids was unchanged or downregulated (data not shown). Taurine suppressed HIF-1-inducible S100C transcription, and addition of taurine (1 mM) to the media suppressed hypoxia-induced upregulation of luciferase activity of the pS100CLUCÀ1948/+93 construct ( Figure 2d ). Gene expression of S100C in cultured rat aortic smooth muscle cells was quantified using the real-time PCR method. S100C expression was upregulated after 9 h of hypoxic incubation. Taurine (1 mM) suppressed the hypoxic induction of S100C (Figure 2e) .
To determine the in vivo effect of taurine on S100C gene expression and the pulmonary vasculature, taurine was administered orally to rats under normoxic and hypoxic conditions. Gene expression of S100C was upregulated after 1 day of hypoxic exposure, and oral taurine administration suppressed the induction (Figure 3) . However, there were no detectable change of HIF-1a expression and DNAbinding activity for hypoxia response element of S100C, by hypoxia and taurine administration. After 12 days of hypoxic exposure, taurine content was increased by oral administration in both normoxic and hypoxic conditions ( Figure 3 ). Using barium-gelatin perfusion, 3 we demonstrated an increase in muscularization of distal pulmonary arteries from 14% in normoxic conditions to 35% in hypoxic conditions. Oral taurine administration attenuated hypoxia-induced muscularization to 27%. The in vivo effect of taurine depletion on the pulmonary vasculature was also investigated by administration of beta-alanine to rats beginning 21 days prior to examination. Beta-alanine inhibits the cellular uptake of taurine and reduces endogenous taurine stores when added to the drinking water. 8 Taurine contents of lungs were decreased in normoxic and hypoxic rats that received beta-alanine, and pulmonary artery muscularization increased to 40% by 12 days of hypoxic exposure, while there was no change in pulmonary artery muscularization in rats exposed to normoxic conditions ( Figure 3 ). Hypoxic exposure also resulted in increased medial wall thickness. Oral taurine administration and taurine depletion had no effect on hypoxia-induced medial wall thickening (data not shown).
DISCUSSION
The present study demonstrated that hypoxia resulted in increased S100C expression and taurine contents in the rat lung, whereas taurine inhibited S100C expression via HIF-1-derived transcriptional regulation in cultured cells. Further, exogenous supplementation increased taurine contents and suppressed hypoxia-induced gene expression.
Transcriptome analysis, a potent strategy to identify potential therapeutic targets, 9 demonstrated hypoxia-induced upregulation of S100C. S100C regulates the cytoske- Figure 3 In vivo effects of taurine administration and depletion in S100C expression and vascular remodeling. Upper, RT-PCR analysis of S100C and beta-actin gene expression in rat lung exposed to hypoxia for 1 day. Middle, changes in taurine content of rat lung exposed to hypoxia or normoxia for 12 days. Lower, the presence of muscularization in normally nonmuscular pulmonary arteries in rat lung exposed to hypoxia or normoxia for 12 days. Graphed data represent mean+SE of n ¼ 4-5. *Po0.05 compared with untreated controls; # Po0.05 compared with untreated hypoxic group; w Po0.05 compared with taurine-treated group. (e) Quantitative analysis of S100C expression by realtime RT-PCR. Total RNAs were isolated from RASMCs incubated for 9 h under hypoxic or normoxic condition. Taurine (1 mM) was added to culture medium 1 h before the experiment. Beta-actin levels measured in the same RNA preparation corrected the relative S100C expression levels. Graphed data represent mean+SE of triplicate. *Po0.05 compared to normoxia.
Target validation in hypoxia-induced vascular remodeling H Amano et al leton via calcium-dependent interactions with annexin I and microfilaments. 10 It is an attractive therapeutic candidate to prevent hypoxic pulmonary vascular remodeling because (a) S100C is abundant in lung tissue, 6 (b) hypoxia results in the upregulation of S100C and (c) S100C possesses hypoxia-response elements in its cis-element. HIF activates transcription of genes encoding hematopoietic growth factor, erythropoietin, angiogenic growth factors and vasomotor regulators, as well as molecules involved in energy metabolism, matrix modeling, iron transport and the regulation of apoptosis/cell proliferation.
1,11 HIF blockade may be of benefit in vascular proliferating diseases, such as tumor angiogenesis.
12-14 Partial HIF-1 deficiency attenuated polycythemia, right ventricular hypertrophy, pulmonary hypertension and pulmonary vascular remodeling in mice exposed to hypoxia. 15 Our FDD analysis demonstrated hypoxia-induced alteration of several interesting candidate genes. We detected the upregulation of insulin-like growth factor-2, one of the HIF-1 regulated gene. 16 Furthermore, we detected the upregulation of several HIF-1 regulated genes (vascular endothelial growth factor, endothelin-1, nitric oxide synthase, adrenomedullin) by RT-PCR analysis in our experimental model (data not shown). However, there was no detectable change in the HIF-1a protein expression and its DNA-binding activity in rat lungs exposed to hypoxia. Using an isolated perfused/ventilated ferret lung preparation, HIF-1a protein expression was reported to be detectable fewer than 4% O 2 concentration by immunoblot, and rapidly degraded with a half-life of o1 min on reoxygenation. 17 These results suggest that our experimental condition (10% O 2 ) may not be enough to produce detectable change in the HIF-1a protein expression and its DNA-binding activity by conventional methods. The precise mechanism of upregulation of S100C protein expression in the hypoxic lung should be elucidated.
On the other hand, we detected the upregulation of taurine content in hypoxic lungs by metabolome analysis. Taurine is a ubiquitous sulfur-containing amino acid, and its release is observed under hypoxic condition at cardiovascular and central nerve systems in several model of ischemic injury in vivo. A considerable portion of taurine release in ischemia is mediated by sodium-dependent manners. 18, 19 In pneumocytes, taurine uptake is dependent on extracellular sodium, and acute hypoxia impairs the sodium transport systems. 20, 21 Taurine has cytoprotective properties and contributes to calcium homeostasis and the regulation of membrane structure and intracellular osmolality. 22 We demonstrated that taurine suppressed the hypoxic upregulation of S100C mRNA through, in part, the inhibition of HIF-1-dependent transcriptional activation in vitro. Further, we demonstrated that exogenous administration of taurine suppressed the hypoxic induction of S100C and attenuate hypoxic vascular remodeling in vivo. We speculated that upregulation of taurine in hypoxic lungs might be a natural compensatory mechanism against acute hypoxic cell damage with its cytoprotective property. We suspected that upregulation of taurine might simultaneously impair the hypoxic gene expression, which promoted the vascular remodeling; however, the level of compensatory mechanism could not overcome the deteriorative effect leading to pulmonary hypertension at the later stage. Thus, exogenous taurine administration might be having therapeutic benefit in treating hypoxia-induced vascular proliferative diseases.
The study of gene expression and mutations forms the basis of functional genomics. Recently, emphasis has shifted to understanding cellular function in terms of the expression of various coded proteins. However, functional regulation of an organism is rarely completely hierarchical. 23 The interactions between metabolic substrates and signaling pathways modify other metabolic functions and gene expression. We simultaneously analyzed hypoxia-induced alterations in gene expression and amino-acid content and identified a therapeutic low-molecular-weight ligand that mediates this process (Figure 4) . We conclude that combined transcriptome and metabolome analysis offers a novel and useful approach to identify molecular candidates for therapeutic intervention.
MATERIALS AND METHODS
Hypoxic Exposure and Drug Treatment
Adult male Sprague-Dawley rats (Nippon CLEA) were kept in a hypobaric hypoxic chamber (air at 380 mmHg) for hypoxic stimulation. Age-matched control rats were kept in a same-sized chamber that was maintained at normal atmospheric pressure. For FDD, lungs were removed to prepare total RNA after 1 and 3 days of hypoxia. The morphometry of lung vasculature was analyzed after 12 days of hypoxia. In addition, taurine was administrated to a group of rats by gavages once daily at a dose of 500 mg/kg/ day. Gavage was initiated 2 days before hypoxic exposure and continued for the entire experimental period. For taurine depletion, rats were maintained on tap water containing 3% beta-alanine, beginning 21 days before the experiment. The Animal Care Committee of Mie University School of Medicine approved all protocols. 
Histopathology
Lung tissues were prepared for morphometric analysis of vasculature using the barium injection method, as previously described.
3 Barium-filled arteries greater than 15 mm in external diameter were assessed for the presence of muscularity. For all normally muscular arteries between 50 and 100 mm in external diameter, the wall thickness was measured along the shortest curvature.
Cells
Primary rat aortic smooth muscle cells (passages 5-8) were maintained in M199 supplemented with 10% FBS and penicillin/streptomycin. Cells between passages 3 and 5 were used for experiments. HeLa cells were maintained in DMEM supplemented with 10% FBS. Hypoxic stimulation (1% O 2 , 5% CO 2 , 94% N 2 ) was provided by incubation in a Napco 7100 incubator.
FDD and Real-time RT-PCR assay
We followed the FDD method developed by Ito et al 5 with several modifications. The real-time RT-PCR assay was performed as described previously. 17 The amount of S100C transcript was standardized by comparison with the betaactin signal.
Immunoblotting Protein samples were subjected to electrophoresis and transferred to a PDVF membrane. Immunoblotting was performed using an antibody raised against purified S100C, and monoclonal anti-HIF-1a antibody (Novus Biochemical) as described previously. 24 Amino-Acid Analysis Lung tissues were homogenized in distilled water, deproteinized with 20% sulfosalicylic acid and centrifuged to remove cellular debris. Samples were mixed with ninhydrin and analyzed by HPLC.
Plasmid
The promoter fragments of S100C were generated by PCR according to previously reported genomic sequence 6 and ligated into the MluI and XhoI site of pGL3-basic plasmid (Promega). The QuikChange site-directed mutagenesis kit (Stratagene) was utilized. All constructs were verified by automatic DNA sequencing.
Transient Transfection and Reporter Assays
Test DNA and pRL-SV40 control vector (Promega) was used for transient transfection of HeLa cells. Transfections were performed in 24-well plates using Tfx-20 (Promega). Cells were subjected to normoxia or hypoxia 24 h after transfection. Luciferase and Renilla luciferase activity of cell lysates were measured by luminometer using the Dual-LuciferaseReporter Assay System (Promega).
Electrophoretic mobility shift assay Nuclear extracts of lung tissues were prepared by using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Pierce Biotechnology). Erythropoietin 3 0 -enhancer oligonucleotide (5 0 -GCC CTA CGT GCC TCG CAT GGC-3 0 ) and S100C 5 0 enhancer oligonucleotide (5 0 -CAA CTG AAA ACG TGG GTC TGG AGT-3 0 ) were labeled with biotinylated ribonucleotides and used as probes. Electrophoretic mobility shift assays were performed by using LightShift Chemiluminescent EMSA Kit (Pierce Biotechnology).
Statistical analysis
Data are presented as mean7SEM. Statistical differences were determined using ANOVA. A P-value of o0.05 was considered statistically significant.
